source clustersSource Clusters is the single source of information on regional development in the life sciences sector worldwide.

With content providing broad overviews as well as in-depth coverage of business development trends, company activities, life science cluster collaborations, multi-partner scientific projects and its extensive news coverage, Source Clusters presents the latest management, research, technology and regional development information serving the needs of executives in the internationally growing life sciences sector.

Source Clusters is the essential resource for companies, incubators, science parks, clusters and regional development agencies looking to find a new location or attract new business and exploit new opportunities across the life sciences sector.

TC BioPharm creates allogeneic cell banks for CAR-T cancer therapy products

TC Biopharm logo 26.1.19CAR-T immuno-oncology product developer TC BioPharm (TCB) has completed the formulation of its first allogeneic gamma-delta T cell banks which provide the company with core technology to develop a deep portfolio of next-generation CAR-T products directed against a wide variety of different cancer types, including both hematological and solid tumours. The project was supported by funding from the European Union’s Horizon 2020 (H2020) Research and Innovation programme via a €4million grant, the largest such EU award to any UK company for development of a health care therapeutic product.

The GDT cell banks are collected and stored from healthy donors, providing a source for TCB to manufacture next-generation ‘off-the-shelf’ GDT cell therapies for future clinical product development. Using allogeneic material from healthy donors offers several advantages over conventional autologous CAR-T therapies, which use the patient’s own cells to treat their tumour, as TCB’s proprietary allogeneic CAR-T cells are not prone to ‘on-target, off-tumour’ toxicities. Additionally, a larger population of cancer patients can be treated with a single reproducible product, ‘campaign-manufactured’ in bulk to keep costs lower, consequently increasing accessibility and reducing financial burden for health care systems.

Benefitting from H2020 support, TCB is rapidly progressing its clinical evaluation of allogeneic therapies and recently demonstrated safety and efficacy of large-dose autologous gamma-delta T cells in cancer patients and commencing treatment of cancer patients with an allogeneic variant. By building on its exclusive CAR-T platform, the company also plans to treat leukemia patients with an allogeneic CD19-directed GDT CAR-T product.

For further information about TC BioPharm visit

Last modified onMonday, 04 February 2019 10:54

Related items

Latest from Tom Mulligan